Drug Trial Radar · NCT06730347
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
May 1, 2025
Primary completion
Jul 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- MacroGenicsIndustry
- Sponsor type
- Industry
- First posted
- Dec 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study CP-MGD019-03 is an open-label study of lorigerlimab in participants with platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer (CCGC). Approximately 80 participants will be enrolled. The study will assess the efficacy and safety of lorigerlimab in participants with PROC or CCGC. Participants will receive lorigerlimab by intravenous (IV) infusion on Day 1 of every 21-day treatment cycle. Treatment cycles will continue until progression of cancer, unacceptable side effects, withdrawal of consent by the participant, or the study ends. Participants will be monitored closely for side effects by physical exam and routine laboratory tests every cycle. Tumor status will be checked approximately every 9 weeks for the first year, then every 12 weeks for the duration of treatment. Participants will have a safety followup performed within 30 days after treatment discontinuation. Participants who discontinue study treatment for reasons other than progression of cancer, will continue CA-125 and tumor assessments every 12 weeks. Participants who discontinue study treatment for progression of cancer will enter the 6-month survival follow up portion of the study.
Conditions
- Platinum-resistant Ovarian Cancer
- Platinum-Resistant Fallopian Tube Carcinoma
- Platinum-Resistant Primary Peritoneal Carcinoma
- Clear Cell Adenocarcinoma of Ovary
- Clear Cell Adenocarcinoma of Vulva
- Clear Cell Adenocarcinoma of Vagina
- Clear Cell Adenocarcinoma of Cervix
- Clear Cell Adenocarcinoma of Uterus
- Clear Cell Adenocarcinoma of Fallopian Tube
- Clear Cell Adenocarcinoma of Peritoneum
- Endometrial Cancer
Interventions
LorigerlimabBiological
Bispecific DART protein binding PD-1 and CTLA-4
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria as determined by the investigatorTime frame: Throughout the study up to approximately 2 years
Locations
16 sites in 3 countries. Site status is shown where the registry gives one.
UCLA
Los Angeles, California · Recruiting
Ochsner MD Anderson Cancer Center
New Orleans, Louisiana · Recruiting
START Midwest
Grand Rapids, Michigan · Recruiting
West Penn Allegheny Health
Pittsburgh, Pennsylvania · Recruiting
The University of Texas MD Anderson Cancer Center, Gynecologic Oncology Center
Houston, Texas · Recruiting
START San Antonio
San Antonio, Texas · Recruiting
Wisconsin Institute Medical Research- UW Cancer Connect
Madison, Wisconsin · Recruiting
Princess Margaret Cancer Center
Toronto, Ontario, Canada · Recruiting
McGill University
Montreal, Quebec, Canada · Recruiting
Yonsei University Health System Severance Hospital
Seoul, South Korea · Recruiting
Gangnam Severance Hospital
Seoul, South Korea · Recruiting
Korea University Guro Hospital
Seoul, South Korea · Recruiting
Seoul National University Hospital
Seoul, South Korea · Recruiting
Samsung Medical Center
Seoul, South Korea · Recruiting
National Cancer Center
Goyang-si, Gyeonggi-do, South Korea · Recruiting
Seoul National University Hospital Bundang Hospital
Seongnam-si, Gyeonnggi-Do, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.